Clinical trials: Stage II Skin Cancer
Mucosal Melanoma, Recurrent Melanoma
Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV
The purpose of this study is to find out how often two investigational drugs that are given together will shrink the patient's tumor and how well they will prolong the time it takes their tumor to grow.
- Conditions
- Mucosal Melanoma, Recurrent Melanoma, Stage IV Melanoma
- Trial name
- NCT01166126
- Testing
- temsirolimus, selumetinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
BRAF or NRAS Mutant Metastatic Melanoma
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
The study will assess the safety and efficacy of single-agent MEK162 in adult patients with locally advanced and unresectable or metastatic malignant cutaneous melanoma, harboring BRAFV600E or NRAS mutations.
- Trial name
- NCT01320085
- Testing
- MEK162
- Where
- 25 sites in United States, Germany and 3 more
- Volunteers
- 183 people
- Sponsor
- Pfizer
Breast Cancer
S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.
RATIONALE: Zoledronate, clodronate, or ibandronate may delay or prevent bone metastases in patients with nonmetastatic breast cancer.
- Trial name
- NCT00127205
- Testing
- clodronate disodium, ibandronate sodium, zoledronic acid
- Volunteers
- 6,097 people
- Sponsor
- SWOG Cancer Research Network
Lymphoma
Study of Total Skin Electron Beam Therapy (TSEBT) in Stage IB-IIIA Mycosis Fungoides
The goal of this clinical research study is to learn if a lower than standard dose of total skin electron beam radiation therapy to the skin can help to control mycosis fungoides.
- Trial name
- NCT01073267
- Testing
- TSEBT
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Triple Negative Breast Cancer, Pancreatic Carcinoma
Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies
The purpose of this study of MCS110 with PDR001 was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the combination of MCS110 with PDR001 in adult patients with…
- Conditions
- Triple Negative Breast Cancer, Pancreatic Carcinoma, Melanoma, Endometrial Carcinoma
- Trial name
- NCT02807844
- Testing
- MCS110, PDR001
- Where
- 20 sites in United States, Belgium and 9 more
- Volunteers
- 141 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer
If residual breast cancer is found in the breast or lymph node tissue removed after preoperative chemotherapy, one may be at increased risk of breast cancer recurrence in the future.
- Trial name
- ABCDE (NCT00925652)
- Testing
- Bevacizumab, Cyclophosphamide, Methotrexate
- Where
- 9 sites in United States
- Volunteers
- 55 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Neoplasms
Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer
The purpose of the study is to address the following hypotheses: (i) Anti-PD-L1 therapy with MEDI4736 administered concomitantly with weekly nab-paclitaxel followed by MEDI4736 concomitant with ddAC neoadjuvant chemotherapy will…
- Trial name
- NCT02489448
- Testing
- MEDI4736
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Yale University
Refractory Cutaneous Melanoma
Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma
The primary objective of this clinical trial is to evaluate the clinical efficacy and progression free survival of the triplet combination of ipilimumab + nivolumab + cabozantinib in patients with anti-PD-1/PD-L1 refractory…
- Trial name
- NCT05200143
- Testing
- Ipilimumab, Nivolumab, Cabozantinib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Providence Health & Services
Breast Cancer, Musculoskeletal Complications
S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy
RATIONALE: Duloxetine hydrochloride may lessen muscle, bone, and joint pain caused by hormone therapy. It is not yet known whether duloxetine hydrochloride is more effective than a placebo in treating patients with muscle, bone…
- Conditions
- Breast Cancer, Musculoskeletal Complications, Pain
- Trial name
- NCT01598298
- Testing
- duloxetine hydrochloride
- Where
- 714 sites in United States
- Volunteers
- 299 people
- Sponsor
- SWOG Cancer Research Network
Locally Advanced Breast Cancer, Metastatic Breast Cancer
Efficacy and Safety of Tenalisib (RP6530), in Patients With Locally Advanced or Metastatic Breast Cancer
Phase II, randomized, open-label study, designed to evaluate the preliminary efficacy and safety of tenalisib at two dose levels in 40 patients with locally advanced or metastatic breast cancer.
- Trial name
- NCT05021900
- Testing
- Tenalisib 800mg, Tenalisib 1200mg
- Where
- 3 sites in Georgia
- Volunteers
- 40 people
- Sponsor
- Rhizen Pharmaceuticals SA
Neoplasms, Neoplasm Metastasis
A Study of AK-01 (LY3295668) in Solid Tumors
This two-part study consists of a phase 1 dose escalation study in participants with locally advanced or metastatic solid tumors, and a phase 2 portion in up to 3 groups with either small cell lung cancer, breast cancer and/or…
- Conditions
- Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms, Head and Neck Neoplasms
- Trial name
- NCT03092934
- Testing
- LY3295668
- Where
- 3 sites in Canada
- Volunteers
- 13 people
- Sponsor
- Eli Lilly and Company
Metastatic Breast Cancer, Recurrent Breast Cancer
VEGF Trap in Treating Patients With Metastatic Breast Cancer
This phase II trial is studying how well VEGF Trap works in treating patients with metastatic breast cancer. VEGF Trap may stop the growth of tumor cells by blocking blood flow to the tumor
- Conditions
- Metastatic Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT00369655
- Testing
- ziv-aflibercept
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Early Breast Cancer
Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients
Phase II, randomized, open-label, international, multicenter study to compare efficacy of standard chemotherapy vs. letrozole plus abemaciclib as neoadjuvant therapy in HR-positive/HER2-negative high/intermediate risk breast…
- Trial name
- CARABELA (NCT04293393)
- Testing
- Doxorubicin, Cyclophosphamide, Taxane
- Where
- 28 sites in Spain
- Volunteers
- 200 people
- Sponsor
- Spanish Breast Cancer Research Group
Breast Cancer
Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer
Phase II trial to explore the efficacy of vorinostat and tamoxifen combined.
- Trial name
- NCT00365599
- Testing
- suberoylanilide hydroxamic acid (SAHA, Vorinostat), tamoxifen citrate (Tamoxifen)
- Where
- 8 sites in United States
- Volunteers
- 43 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Melanoma
Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI
The goals of this study are to 1) assess the safety of recombinant MAGE-A3 protein combined with AS15 Immunological Adjuvant System (recMAGE-A3 + AS15) as an Antigen-Specific Cancer Immunotherapeutic (MAGE-A3 ASCI) when…
- Trial name
- Mel55 (NCT01425749)
- Testing
- recMAGE-A3 + AS15 ASCI
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Craig L Slingluff, Jr
Breast Cancer, Breast Neoplasms
Vaccination of High Risk Breast Cancer Patients - A Combined Phase I/II Feasibility-and-Efficacy Study
The purpose of this study is to evaluate a new investigational cancer vaccine, P10s-PADRE in combination with standard neoadjuvant chemotherapy and surgery in patients with clinical stage I, II or III estrogen-receptor…
- Trial name
- NCT02229084
- Testing
- P10s-PADRE/ MONTANIDE™ ISA 51 VG, Doxorubicin, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 58 people
- Sponsor
- University of Arkansas
Metastatic Breast Cancer
Efficacy Study of Gemcitabine-Paclitaxel to Treat Metastatic Breast Cancer
The purpose of this study is to determine the response rate to a gemcitabine-paclitaxel combination administered on a 3-weekly schedule in Chinese patients with unresectable, locally recurrent breast cancer or metastatic breast…
- Trial name
- NCT00316199
- Testing
- gemcitabine, paclitaxel
- Where
- 3 sites in China
- Volunteers
- 60 people
- Sponsor
- Eli Lilly and Company
Unresectable Melanoma, Metastatic Melanoma
A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma
This is a multicenter, open label, Phase 2 study, with 3 parallel cohorts. The aim of the study is to evaluate the efficacy of sotigalimab (APX005M) administered at 2 different schedules to adult participants with unresectable or…
- Conditions
- Unresectable Melanoma, Metastatic Melanoma, Cancer, Cancer of Skin
- Trial name
- NCT04337931
- Testing
- sotigalimab
- Where
- 19 sites in Poland, Spain
- Volunteers
- 45 people
- Sponsor
- Apexigen America, Inc.
Recurrent Melanoma, Stage III Skin Melanoma
MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma
This phase II trial is studying how well MEK inhibitor AZD6244 works in treating patients with stage III or stage IV melanoma. MEK inhibitor AZD6244 may stop the growth of tumor cells by blocking some of the enzymes needed for…
- Conditions
- Recurrent Melanoma, Stage III Skin Melanoma, Stage IV Skin Melanoma
- Trial name
- NCT00866177
- Testing
- Laboratory Biomarker Analysis, Selumetinib
- Where
- United States
- Volunteers
- 167 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Breast Cancer, Liver Metastases
Intra-hepatic Chemotherapy in Patients With Liver Metastases From Breast Cancer and Limited Extrahepatic Disease
This is a phase II trial evaluating intra-hepatic chemotherapy with oxaliplatin every second week in combination with systemic capecitabine and in patients with a HER2-positive tumour in combination with trastuzumab (Herceptin®)…
- Trial name
- NCT01387295
- Testing
- oxaliplatin, capecitabine, trastuzumab
- Where
- Denmark
- Volunteers
- 38 people
- Sponsor
- Dorte Nielsen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.